CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. (CNSP): 3 pipeline candidates · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.1 months
D/E 64.81 · 0% dilution
Lead: Phase 2
3 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for CNS Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.9M
Cash
$3.0M
Quarterly Burn
$4.6M
Runway
2.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$88K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 23,189 | $56K |
| boothbay fund management, llc | 13,524 | $32K |
| barrett & company, inc. | 8 | $19 |
| caitong international asset management co., ltd | 1 | $2 |
| citigroup inc | 1 | $2 |
| danske bank a/s | 1 | $2 |
Frequently asked questions
How many drug candidates are in CNS Pharmaceuticals, Inc.'s pipeline?
CNS Pharmaceuticals, Inc. (CNSP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CNS Pharmaceuticals, Inc.'s lead drug candidate?
CNS Pharmaceuticals, Inc.'s most advanced tracked candidate is Berubicin (Phase 2) for Glioblastoma Multiforme, Adult.
What is CNS Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CNS Pharmaceuticals, Inc. has approximately 2.1 months of cash runway.
What is CNS Pharmaceuticals, Inc.'s market capitalization?
CNS Pharmaceuticals, Inc.'s market capitalization is approximately $6.9M.
Who is the CEO of CNS Pharmaceuticals, Inc.?
Mr. Rami Levin M.B.A. is the chief executive officer of CNS Pharmaceuticals, Inc. (CNSP).
Get the full picture on CNS Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.